Renzhi Liu

Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist

ABSTRACT Aims This study assessed the preclinical and clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors....